Serum levels of soluble urokinase plasminogen activator receptor in juvenile idiopathic arthritis: a single-center Swedish case-control study

Abstract Objectives Reliable biomarkers in the early stages of idiopathic arthritis (JIA) are scarce and the disease heterogeneity makes it clinically challenging to predict the risk of joint damage. Biomarkers with prognostic potential are warranted in order to individualize treatment and follow-up...

Full description

Bibliographic Details
Main Authors: Per Lewander, Lina Wirestam, Charlotte Dahle, Jonas Wetterö, Christopher Sjöwall
Format: Article
Language:English
Published: BMC 2023-05-01
Series:Pediatric Rheumatology Online Journal
Subjects:
Online Access:https://doi.org/10.1186/s12969-023-00832-9
_version_ 1797811613364912128
author Per Lewander
Lina Wirestam
Charlotte Dahle
Jonas Wetterö
Christopher Sjöwall
author_facet Per Lewander
Lina Wirestam
Charlotte Dahle
Jonas Wetterö
Christopher Sjöwall
author_sort Per Lewander
collection DOAJ
description Abstract Objectives Reliable biomarkers in the early stages of idiopathic arthritis (JIA) are scarce and the disease heterogeneity makes it clinically challenging to predict the risk of joint damage. Biomarkers with prognostic potential are warranted in order to individualize treatment and follow-up in JIA. The soluble urokinase plasminogen activator receptor (suPAR) has been reported as an easily measurable biomarker for prognosis and severity in several rheumatic diseases but it has never been studied in JIA. Methods Sera from 51 well-characterized patients with JIA and 50 age- and sex-matched control subjects were collected and stored for later analysis of suPAR. Patients were carefully followed clinically over 3 years and analysis of erythrocyte sedimentation rate, C-reactive protein, rheumatoid factor (RF) and antibodies against cyclic citrullinated peptides (anti-CCP) were analyzed as part of clinical routine. Signs of joint erosions were evaluated by radiography. Results Overall, the levels of suPAR did not differ significantly between JIA patients and controls but those with polyarticular involvement showed higher suPAR (p = 0.013). In addition, elevated suPAR were associated with joint erosions (p = 0.026). Two RF/anti-CCP negative individuals with erosions showed high levels of suPAR. Conclusions We present new data on the biomarker suPAR in JIA. Our results indicate that, apart from RF and anti-CCP, analysis of suPAR could be of additional value in assessing the risk of erosions. Analysis of suPAR early could potentially guide treatment decision-making in JIA, but our observations should be confirmed in prospective studies.
first_indexed 2024-03-13T07:25:18Z
format Article
id doaj.art-59e52195b3b4430eabf1ebda57c89523
institution Directory Open Access Journal
issn 1546-0096
language English
last_indexed 2024-03-13T07:25:18Z
publishDate 2023-05-01
publisher BMC
record_format Article
series Pediatric Rheumatology Online Journal
spelling doaj.art-59e52195b3b4430eabf1ebda57c895232023-06-04T11:23:29ZengBMCPediatric Rheumatology Online Journal1546-00962023-05-012111710.1186/s12969-023-00832-9Serum levels of soluble urokinase plasminogen activator receptor in juvenile idiopathic arthritis: a single-center Swedish case-control studyPer Lewander0Lina Wirestam1Charlotte Dahle2Jonas Wetterö3Christopher Sjöwall4Department of Paediatrics, Vrinnevi HospitalDepartment of Biomedical and Clinical Sciences, Division of Inflammation and Infection/Rheumatology, Linköping UniversityDepartment of Biomedical and Clinical Sciences, Division of Inflammation and Infection/Clinical Immunology, Linköping UniversityDepartment of Biomedical and Clinical Sciences, Division of Inflammation and Infection/Rheumatology, Linköping UniversityDepartment of Biomedical and Clinical Sciences, Division of Inflammation and Infection/Rheumatology, Linköping UniversityAbstract Objectives Reliable biomarkers in the early stages of idiopathic arthritis (JIA) are scarce and the disease heterogeneity makes it clinically challenging to predict the risk of joint damage. Biomarkers with prognostic potential are warranted in order to individualize treatment and follow-up in JIA. The soluble urokinase plasminogen activator receptor (suPAR) has been reported as an easily measurable biomarker for prognosis and severity in several rheumatic diseases but it has never been studied in JIA. Methods Sera from 51 well-characterized patients with JIA and 50 age- and sex-matched control subjects were collected and stored for later analysis of suPAR. Patients were carefully followed clinically over 3 years and analysis of erythrocyte sedimentation rate, C-reactive protein, rheumatoid factor (RF) and antibodies against cyclic citrullinated peptides (anti-CCP) were analyzed as part of clinical routine. Signs of joint erosions were evaluated by radiography. Results Overall, the levels of suPAR did not differ significantly between JIA patients and controls but those with polyarticular involvement showed higher suPAR (p = 0.013). In addition, elevated suPAR were associated with joint erosions (p = 0.026). Two RF/anti-CCP negative individuals with erosions showed high levels of suPAR. Conclusions We present new data on the biomarker suPAR in JIA. Our results indicate that, apart from RF and anti-CCP, analysis of suPAR could be of additional value in assessing the risk of erosions. Analysis of suPAR early could potentially guide treatment decision-making in JIA, but our observations should be confirmed in prospective studies.https://doi.org/10.1186/s12969-023-00832-9Soluble urokinase plasminogen activator receptorJuvenile idiopathic arthritisJoint damageBiomarker
spellingShingle Per Lewander
Lina Wirestam
Charlotte Dahle
Jonas Wetterö
Christopher Sjöwall
Serum levels of soluble urokinase plasminogen activator receptor in juvenile idiopathic arthritis: a single-center Swedish case-control study
Pediatric Rheumatology Online Journal
Soluble urokinase plasminogen activator receptor
Juvenile idiopathic arthritis
Joint damage
Biomarker
title Serum levels of soluble urokinase plasminogen activator receptor in juvenile idiopathic arthritis: a single-center Swedish case-control study
title_full Serum levels of soluble urokinase plasminogen activator receptor in juvenile idiopathic arthritis: a single-center Swedish case-control study
title_fullStr Serum levels of soluble urokinase plasminogen activator receptor in juvenile idiopathic arthritis: a single-center Swedish case-control study
title_full_unstemmed Serum levels of soluble urokinase plasminogen activator receptor in juvenile idiopathic arthritis: a single-center Swedish case-control study
title_short Serum levels of soluble urokinase plasminogen activator receptor in juvenile idiopathic arthritis: a single-center Swedish case-control study
title_sort serum levels of soluble urokinase plasminogen activator receptor in juvenile idiopathic arthritis a single center swedish case control study
topic Soluble urokinase plasminogen activator receptor
Juvenile idiopathic arthritis
Joint damage
Biomarker
url https://doi.org/10.1186/s12969-023-00832-9
work_keys_str_mv AT perlewander serumlevelsofsolubleurokinaseplasminogenactivatorreceptorinjuvenileidiopathicarthritisasinglecenterswedishcasecontrolstudy
AT linawirestam serumlevelsofsolubleurokinaseplasminogenactivatorreceptorinjuvenileidiopathicarthritisasinglecenterswedishcasecontrolstudy
AT charlottedahle serumlevelsofsolubleurokinaseplasminogenactivatorreceptorinjuvenileidiopathicarthritisasinglecenterswedishcasecontrolstudy
AT jonaswettero serumlevelsofsolubleurokinaseplasminogenactivatorreceptorinjuvenileidiopathicarthritisasinglecenterswedishcasecontrolstudy
AT christophersjowall serumlevelsofsolubleurokinaseplasminogenactivatorreceptorinjuvenileidiopathicarthritisasinglecenterswedishcasecontrolstudy